“duchenne-muscular-dystrophy” Archives

in
Entry Author Date Location
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More 10/09/20 National
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More 10/02/20 National
FDA Lifts Solid Bio Clinical Hold, Duchenne Study Cleared to Resume 10/01/20 Boston
Bio Roundup: COVID-19 Pact, Gavreto Approval, Generative Biology & More 09/11/20 National
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases 08/26/20 Boston
Bio Roundup: Seres Soars, MesoBlast Vote, Duchenne Decision & More 08/14/20 National
With FDA Nod, NS Pharma Duchenne Drug Becomes Sarepta Competitor 08/12/20 New York
Sarepta Eyes Key Test for Gene Therapy in Rare Muscular Dystrophy 06/08/20 Boston
Neurology at Forefront of FDA’s Complex Innovative Trial Design Pilot 04/16/20 National
Bio Roundup: Goodbye Belviq, LogicBio on Hold, Revolution’s IPO & More 02/14/20 National
Wave Life Sciences’ Stumble in Duchenne Leads to 22% Staff Layoff 02/10/20 Boston
Bio Roundup: Coronavirus Concerns, Sarepta’s CRL, Eye Drug OK’d & More 01/24/20 National
FDA Flags Risk of Infection, Kidney Damage for Sarepta Duchenne Drugs 01/22/20 Boston
Solid Bio Restructures to Get Halted Gene Therapy Study Back on Track 01/09/20 Boston
Wave Stock Crashes After Decision to Halt Duchenne Drug Studies 12/16/19 Boston
Bio Roundup: Sarepta’s Approval, Merck M&A, Drug Price Bill & More 12/13/19 National
In an About-Face, FDA Approves Second Sarepta Muscular Dystrophy Drug 12/13/19 Boston
Avidity Bio Adds $100M to Advance R&D of Muscle Disorder Drugs 11/13/19 San Diego
FDA Again Halts Solid Bio’s Duchenne Gene Therapy Clinical Trial 11/12/19 Boston
Bio Roundup: PARP Progress, A New Commish, IPO-Palooza & More 10/04/19 National
Phil Sharp, CRISPR’ing the Heart & the Duchenne Data Gap on Oct. 17 09/11/19 Boston
Vertex Bets $950M on Semma and a Stem Cell Therapy for Diabetes 09/03/19 Boston
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More 08/30/19 National
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More 08/23/19 National
FDA Rejects Sarepta’s Second Duchenne Drug, Citing Safety Concerns 08/19/19 Boston
Bio Roundup: Zolgensma Fallout, Duchenne Redux, Ebola Boost & More 08/16/19 National
Four New Drugs Are Around the Corner. Here’s What You Need to Know. 08/15/19 National
Bio Roundup: Surprise News, a Gene Therapy Mess & a CAR-T Step 08/09/19 National
Amicus Offers First Look At Gene Therapy Work With Batten’s Data 08/01/19 New York
Duchenne Advocates Start Casimir, Aiming to Capture Missing Data 07/26/19 Boston
Page 1 of 8 next page »